Gunzler Douglas, Bleyer Anthony J, Thomas Robert L, O'Brien Alicia, Russell Gregory B, Sattar Abdus, Iyengar Sudha K, Thomas Charles, Sedor John R, Schelling Jeffrey R
BMC Nephrol. 2013 Jun 17;14:124. doi: 10.1186/1471-2369-14-124.
Diabetic nephropathy is a growing clinical problem, and the cause for >40% of incident ESRD cases. Unfortunately, few modifiable risk factors are known. The objective is to examine if albuminuria and history of diabetic nephropathy (DN) in a sibling are associated with early DN progression or mortality.
In this longitudinal study of adults >18 yrs with diabetes monitored for up to 9 yrs (mean 4.6 ± 1.7 yrs), 435 subjects at high risk (DN family history) and 400 at low risk (diabetes >10 yrs, normoalbuminuria, no DN family history) for DN progression were evaluated for rate of eGFR change using the linear mixed effects model and progression to ESRD. All-cause mortality was evaluated by Kaplan-Meier analyses while controlling for baseline covariates in a Cox proportional hazards model. Covariates included baseline eGFR, age, gender, race, diabetes duration, blood pressure, hemoglobin A1c and urine albumin:creatinine ratio. Propensity score matching was used to identify high and low risk group pairs with balanced covariates. Sensitivity analyses were employed to test for residual confounding.
Mean baseline eGFR was 74 ml/min/1.73 m2 (86% of cohort >60 ml/min/1.73 m2). Thirty high risk and no low risk subjects developed ESRD. eGFR decline was significantly greater in high compared to low risk subjects. After controlling for confounders, change in eGFR remained significantly different between groups, suggesting that DN family history independently regulates GFR progression. Mortality was also significantly greater in high versus low risk subjects, but after controlling for baseline covariates, no significant difference was observed between groups, indicating that factors other than DN family history more strongly affect mortality. Analyses of the matched pairs confirmed change in eGFR and mortality findings. Sensitivity analyses demonstrated that the eGFR results were not due to residual confounding by unmeasured covariates of a moderate effect size in the propensity matching.
Diabetic subjects with albuminuria and family history of DN are vulnerable for early GFR decline, whereas subjects with diabetes for longer than 10 years, normoalbuminuria and negative family history, experience slower eGFR decline, and are extremely unlikely to require dialysis. Although we would not recommend that patients with low risk characteristics be neglected, scarce resources would be more sensibly devoted to vulnerable patients, such as the high risk cases in our study, and preferably prior to the onset of albuminuria or GFR decline.
糖尿病肾病是一个日益严重的临床问题,是超过40%的新发终末期肾病病例的病因。遗憾的是,已知的可改变风险因素很少。目的是研究同胞中的蛋白尿和糖尿病肾病(DN)病史是否与早期DN进展或死亡率相关。
在这项对18岁以上糖尿病成年人进行的长达9年(平均4.6±1.7年)的纵向研究中,对435名高风险(有DN家族史)和400名低风险(糖尿病病程>10年、正常白蛋白尿、无DN家族史)的DN进展受试者,使用线性混合效应模型评估估算肾小球滤过率(eGFR)变化率以及进展至终末期肾病的情况。通过Kaplan-Meier分析评估全因死亡率,同时在Cox比例风险模型中控制基线协变量。协变量包括基线eGFR、年龄、性别、种族、糖尿病病程、血压、糖化血红蛋白A1c和尿白蛋白:肌酐比值。采用倾向评分匹配来识别协变量平衡的高风险和低风险组对。进行敏感性分析以检验残余混杂情况。
平均基线eGFR为74 ml/min/1.73m²(队列中86%>60 ml/min/1.73m²)。30名高风险受试者进展至终末期肾病,无低风险受试者进展至该病。高风险受试者的eGFR下降明显大于低风险受试者。在控制混杂因素后,两组之间的eGFR变化仍存在显著差异,这表明DN家族史独立调节肾小球滤过率进展。高风险受试者的死亡率也显著高于低风险受试者,但在控制基线协变量后,两组之间未观察到显著差异,这表明除DN家族史外的其他因素对死亡率的影响更大。对匹配组的分析证实了eGFR变化和死亡率的研究结果。敏感性分析表明,eGFR结果并非归因于倾向匹配中效应量中等的未测量协变量造成的残余混杂。
有蛋白尿和DN家族史的糖尿病患者易出现早期肾小球滤过率下降,而糖尿病病程超过10年、正常白蛋白尿且家族史阴性的患者,其肾小球滤过率下降较慢,且极不可能需要透析。虽然我们不建议忽视具有低风险特征的患者,但稀缺资源更合理地应用于易患病患者,如我们研究中的高风险病例,最好在出现蛋白尿或肾小球滤过率下降之前。